Skip to main navigation Skip to search Skip to main content

Prevención de enfermedad hemolítica perinatal severa con inmunoglobulina intravenosa en paciente altamente sensibilizada

Translated title of the contribution: Prevention of severe perinatal hemolytic disease with intravenous immunoglobulin in a highly sensitized patient
  • Catalina Villalobos Andueza
  • , Manuel José Monckeberg Balmaceda
  • , Cristian Kottman González
  • , Juan Carlos Arteaga Rocuant
  • , Enrique Oyarzún Ebensperger*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Perinatal Hemolytic Disease is uncommon today due to its prevention. However, there are cases of highly sensitized mothers who wish to have a child, that forces this desired pregnancy to be controlled in a special way and be subjected to invasive procedures not exempt from fetal morbidity and mortality. Prenatal use of human inmunoglobulin in the mother may represent a therapeutic alternative. We present a case in which its use prevented the development of intrauterine disease and favored a good neonatal evolution despite the fact that the initial prognosis was very adverse.

Translated title of the contributionPrevention of severe perinatal hemolytic disease with intravenous immunoglobulin in a highly sensitized patient
Original languageSpanish
Pages (from-to)76-80
Number of pages5
JournalRevista Chilena de Obstetricia y Ginecologia
Volume86
Issue number1
DOIs
StatePublished - Feb 2021

Bibliographical note

Publisher Copyright:
© 2021 Sociedad Chilena de Obstetricia y Ginecologia. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Prevention of severe perinatal hemolytic disease with intravenous immunoglobulin in a highly sensitized patient'. Together they form a unique fingerprint.

Cite this